{"nctId":"NCT01980524","briefTitle":"The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes","startDateStruct":{"date":"2013-10"},"conditions":["Type 2 Diabetes"],"count":8,"armGroups":[{"label":"acipimox+","type":"EXPERIMENTAL","interventionNames":["Drug: acipimox"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Oral Capsule"]}],"interventions":[{"name":"acipimox","otherNames":[]},{"name":"Placebo Oral Capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes\n* HbA1C \\>6%\n\nExclusion Criteria:\n\n* Insulin therapy (except: BOT=basal supported oral therapy)\n* Known heart disease including coronary artery disease, cardiomyopathy, history of cardiac surgery\n* Known intolerance against niacins\n* Known contra-indications against magnetic resonance (MR-) examinations","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"MYCL","description":"Intramyocardiocellular lipid content (MYCL) before and after administration of acipimox or placebo","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.1"},{"groupId":"OG001","value":"0.44","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.2"},{"groupId":"OG001","value":"0.36","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Ejection Fraction","description":"Left ventricular ejection fraction before and after administration of acipimox or placebo","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":"6"},{"groupId":"OG001","value":"78","spread":"8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":"9"},{"groupId":"OG001","value":"77","spread":"7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Stroke Volume","description":"Stroke volume before and after administration of acipimox or placebo","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":"10"},{"groupId":"OG001","value":"36","spread":"6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":"8"},{"groupId":"OG001","value":"36","spread":"6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":[]}}}